Financial Results (Consolidated, Unaudited, INR Lakhs)

Income Statement for Quarter Ended June 30, 2026:

  • Revenue from operations: ₹1,917.42
  • Other income: ₹13.32
  • Total Income: ₹1,930.74
  • Cost of material consumed: ₹30.02
  • Purchase of stock in trade: ₹952.31
  • Changes in inventories of stock in trade: ₹82.51
  • Purchase of services: ₹104.77
  • Employees benefit expenses: ₹599.69
  • Finance costs: ₹36.32
  • Depreciation and amortization expense: ₹100.89
  • Other expenses: ₹381.72
  • Total Expenses: ₹2,288.24
  • Profit/(Loss) before tax: (₹357.50)
  • Total tax expense: ₹17.46
  • Net profit/(Loss) for the period: (₹374.95)
  • Attributable to Shareholders of the Company: (₹190.24)
  • Attributable to Non-controlling interest: (₹184.71)
  • Total comprehensive income for the period: (₹373.34)
  • Attributable to Shareholders: (₹189.41)
  • Attributable to Non-controlling interest: (₹183.94)

Comparative Figures:

  • Q4 FY26 (Mar 31, 2026) Net Profit: ₹677.97 lakh
  • Q1 FY25 (Jun 30, 2025) Net Loss: (₹342.62) lakh
  • FY26 (Mar 31, 2026) Net Loss: (₹475.05) lakh

Earnings Per Share (Face value ₹10 each):

  • Basic EPS: (₹9.44)
  • Diluted EPS: Not Annualized

Paid-up equity share capital: ₹200.69 lakh (unchanged)

Segment Reporting (INR Lakhs)

Revenue by Business Segment (Q1 FY27):

  • Sale of Merchandise: ₹1,235.73
  • Supply of IT services: ₹506.35
  • Supply of other services: ₹0.00
  • Income from hospital services: ₹153.99
  • Sale of pharmacy products: ₹1.35
  • Total: ₹1,917.42

Geographical Segment (Q1 FY27):

  • Within India: ₹1,782.45
  • Outside India: ₹134.97
  • Total: ₹1,917.42

Subsidiary Updates

1. eYantra Ventures FZE, UAE: The Board decided on July 2, 2026 to close/strike off this non-functioning wholly owned subsidiary. For Q1 FY27, it reported:

  • Total Revenue: Nil
  • Net Loss after tax: (₹17.35)
  • Comprehensive loss: (₹17.35)

2. Prismberry Technologies Private Limited: The National Company Law Tribunal, Hyderabad approved the merger with the company via Order No. CA(CAA) 24/230/HDB/2026 dated July 15, 2026. The appointed date for the scheme is April 1, 2026. The merger will become effective after NCLT approval under Companies Act, 2013. Results are included in consolidation.

3. Neuro and Spine Associates Private Limited: Contributed to consolidated results with:

  • Total Revenue: ₹160.28
  • Net Loss after tax: (₹384.17)
  • Comprehensive loss: (₹382.56)

4. EYANTRA VENTURES INC (USA): Incorporated May 8, 2025, authorized to issue 10,000 shares of common stock ($0.0001 par value). No shares subscribed as of June 30, 2026. No business operations commenced.

Auditor Review

PRSV & Co LLP issued a limited review report stating nothing came to their attention suggesting material misstatement. The review was conducted in accordance with SRE 2410 and SEBI circular under Regulation 33(8).

Accounting Policies

The unaudited Consolidated Financial Results prepared in accordance with Indian Accounting Standards (IndAS) prescribed under Section 133 of Companies Act, 2013. Investment and advances given to eYantra Ventures FZE are impaired/ECL provided in standalone financials, net of deferred tax.